RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) on April 3 and set a price target ...
RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst (BCRX – Research Report) on April 3 and set a price target of $11.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback